MedTrace Logo

The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters.

NCT03850314 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-02-21

No results posted yet for this study

Summary

The current study will test the central hypothesis that Glycine supplementation in humans improves Lipid profile and therefore reduces the risk of Atherosclerosis. Secondary outcomes including Insulin sensitivity and parameters related to Metabolic Syndrome (MetS) will also be measured. Furthermore, a mechanistic study in an ex-vivo model will test the hypothesis that Glycine via its key biosynthetic pathway involving Serine Hydroxymethyltransferase 2 (SHMT2), is athero-protective by inhibiting Sterol regulatory element-binding protein 2 (SREBP2)-mediated cholesterol biosynthesis in murine macrophage-like cell line.

Conditions

Interventions

DIETARY_SUPPLEMENT

Glycine

Glycine powder to be dissolved in water.

Sponsors & Collaborators

  • Prof. Tony hayek MD

    lead OTHER

Principal Investigators

  • Tony Hayek, MD · Rambam Health Care Campus

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2019-12-31
Completion
2020-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850314 on ClinicalTrials.gov